- Details
- Joining Alicia Morgans is Robert Dreicer highlighting a currently enrolling Phase III trial of sabizabulin, an oral cytoskeleton disruptor in mCRPC. The VERACITY trial s a blinded trial of 245 patients randomized to two to one drug, to the alternative ARI. Dr. Dreicer describes the rationale for the trial, the trial design, and the eligibility criteria. Biographies: Robert Dreicer, MD, MS, MACP, F...
|
- Details
- Gerhardt Attard joins Alicia Morgans to discuss a combined analysis from two comparisons in the STAMPEDE platform. Dr. Gerhardt Attard presented a combined analysis from the STAMPEDE platform assessing the role of abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0...
|
- Details
- Dr Scott Tagawa discusses the reported results of a phase I/II study of dose-escalation study of a fractionated (dose-dense) treatment regime of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC) in this conversation with Dr Alicia Morgans. Previously reported, the initial phase I data from this study demonstrated no evidence of short-term dose-limiting toxicity. Dr Tagawa...
|
- Details
- In this UroToday discussion between Alicia Morgans and Michael Schweizer, they discuss a single-center phase II trial that combined testosterone therapy with olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Schweizer discusses why he and his team were interested in this study. Dr. Schweizer mentions preclinical observations in cancer cell lines, that mimic the...
|
- Details
- Alicia Morgans is joined by Bertrand Tombal who is highlighting two subgroup analyses from the phase III HERO trial reported at the 2021 European Society of Medical Oncology meeting. They discuss a subgroup analysis of the phase 3 HERO study assessing the efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer as well as a subgroup analysis assessing geographical...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the recent analysis of the PEACE-1 study. The PEACE-1 study is a phase 3 trial evaluating abiraterone plus standard of care in M1 disease and local radiation therapy directed to the prostate primary. Dr. Fizazi discusses the study design and the first results he presented at ASCO 2021, specifically treatment with androgen deprivation therapy (ADT), docetaxel...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the VISION trial, evaluating new patient-reported data. This patient-reported health-related quality of life data was presented at ESMO 2021. They discuss the VISION trial design, primary trial endpoints, and the importance of preserving good patient quality of life during advanced prostate cancer treatment. Biographies: Karim Fizazi, MD, Ph.D., is a medical...
|
- Details
- Alicia Morgans converses with Scott Tagawa about patient-reported outcomes in men undergoing PSMA targeted radiopharmaceutical treatments for prostate cancer. The discussion centers on a Department of Defense-funded study that aims to develop a new patient-reported outcome tool specifically for this patient population. Dr. Tagawa elaborates on the instruments commonly used in clinical trials, such...
|
- Details
- In this conversation, Scott Tagawa and Oliver Sartor join Charles Ryan in a discussion on the PSMAddition clinical trial that integrates lutetium-177 with standard-of-care therapy in metastatic castration-sensitive prostate cancer (mCSPC). The trial aims to determine the efficacy and safety of lutetium-177 administered earlier in the disease course. They believe that using lutetium-177 upfront wil...
|
